Klow Blend 110

Klow Blend 110 is the higher-dosed version of Klow Blend. One vial holds 110mg of active compounds: 50mg GHK-Cu, 20mg BPC-157, 20mg TB-500 (thymosin beta-4) and 20mg KPV. The regular Klow vial holds 80mg, made up of 50mg GHK-Cu and 10mg of each of the three peptides. So the copper component stays the same while BPC-157, TB-500 and KPV are doubled.

That shifts the ratio. In Klow Blend, GHK-Cu makes up a good 60 percent of the contents; in Klow Blend 110 it is around 45 percent. The three peptides together account for 55 percent. The K in the name still stands for KPV, the anti-inflammatory tripeptide that extends the Glow stack of BPC-157, TB-500 and GHK-Cu. All four building blocks also have their own lexicon entries with the details of each mechanism.

The vial comes as lyophilised powder that you reconstitute with bacteriostatic water. There are no controlled human studies of this fixed four-way combination; the evidence comes from preclinical research on the individual components.

This information is for research and educational purposes only. No medical advice.

The four components act at different points of tissue repair. BPC-157 is a pentadecapeptide derived from a protein in gastric juice; in animal models it promotes new blood vessel formation, activates growth factor signalling in tendon and ligament cells and so speeds up soft tissue repair (Gwyer 2019). TB-500 corresponds to thymosin beta-4, a 43-amino-acid peptide that binds actin, drives cells to migrate into injured tissue and, in a wound model, increased re-epithelialisation, collagen deposition and angiogenesis (Malinda 1999).

GHK-Cu is a naturally occurring tripeptide that binds copper and whose plasma level declines with age. In cell and gene expression data it modulates the activity of thousands of genes toward repair: more collagen, elastin and decorin, fewer inflammatory and degradative signals (Pickart 2018). KPV is the C-terminal tripeptide of alpha-MSH. It is taken up via the peptide transporter PepT1 into intestinal epithelial and immune cells, where it dampens NF-kB and MAP kinase signalling; in mouse colitis models inflammation fell clearly (Dalmasso 2008).

In the blend this runs in parallel: repair and angiogenesis through BPC-157 and TB-500, connective tissue and skin through GHK-Cu, inflammation control through KPV. Compared with the regular Klow, the same total amount per shot gives you around 45 percent more of each of the three peptides and a good quarter less copper. Whether the effects add up or merely sit side by side has not been studied; there are no studies on the combination.

The kit is the same as for the individual healing peptides:

• The Klow Blend 110 vial with the lyophilised powder (four compounds, 110mg)
• Bacteriostatic water for reconstitution, 2 or 3ml per vial (one 3ml bottle is enough for one vial)
• U-100 insulin syringes
• Alcohol swabs for the vial cap and the skin
• A sealable container for used needles

Because the solution is concentrated (around 37mg per ml with 3ml of water), doses come out as only a few units. A syringe with a fine scale or half-unit markings makes reading easier.

All figures refer to the total amount of the four compounds; the proportions stay fixed in every dose. With 3ml of bacteriostatic water on 110mg you get around 36.7mg per ml: 2.2mg total is then 6 units on the U-100 syringe and 1.1mg is 3 units. With 2ml the solution is 55mg per ml, 2.2mg is 4 units and 1.1mg is 2 units.

The calculator above works this out for any water volume. 3ml is the more comfortable standard because the units are not quite as small and the solution is less concentrated. Both volumes put both dose steps on whole units.

Just add the water to the vial; it does not matter whether it hits the powder directly. Then swirl or shake until everything is clearly dissolved, both are fine. The copper in GHK-Cu tints the solution blue, which is normal and not a quality issue.

Inject subcutaneously into the fat layer under the skin, classically the abdomen (keep two finger widths clear around the navel), the front of the thigh or the back of the upper arm. For a local target such as an irritated tendon, BPC-157 is often injected close to the site; that works with the blend too, though the other components spread through the body anyway.

• Clean the skin with an alcohol swab and let it dry briefly
• Lift a small fold of skin
• Insert the needle at 45 to 90 degrees
• Inject, slowly or briskly both work, wait a moment, then withdraw the needle
• Put the needle straight into the sharps container

Rotate the injection site from day to day. The copper component can be a little more irritating locally than pure peptide solutions; a clean stick and rotating sites keep that small.

There is no study of the combination itself, neither preclinical nor in humans. What exists is work on the four building blocks, almost all of it from cell and animal models. For BPC-157 a review (Gwyer 2019) sums up the data on tendon, ligament and muscle repair: consistently positive findings, but almost exclusively in rodents and from only a handful of research groups, with confirmation in humans still pending.

For thymosin beta-4 the rat wound model (Malinda 1999) showed clearly faster re-epithelialisation with more collagen and new vessels, both topically and after injection. A later review from the developer's side (Crockford 2010) describes cell migration, vessel formation and modulation of inflammation as the rationale for clinical trials in skin, cornea and heart; thymosin beta-4 is still not approved as a medicine in the EU or the US. GHK-Cu is mechanistically well described through Pickart's work, modulating more than 4000 genes toward regeneration in gene expression data (Pickart 2018), but the evidence is mostly topical and cosmetic, with little on injection in humans.

KPV has its cleanest foundation in the gut: in cell experiments it inhibited NF-kB and MAP kinase signalling at nanomolar concentrations. Given orally, it reduced inflammation in two mouse colitis models (Dalmasso 2008). Whether the effects work together in the blend remains an assumption drawn from the complementary mechanisms. You find the studies with links in the source block below.

All four components are considered well tolerated in the preclinical literature. That matches user reports on the regular Klow Blend. Injection site reactions are the most common: mild redness, a feeling of pressure or transient irritation. The copper component can amplify that locally; rotating sites helps.

• Copper balance: GHK-Cu brings copper with it, around 16 percent of its weight. At 1 to 1.5mg GHK-Cu daily that is roughly 0.15 to 0.25mg of copper per day, less than a normal diet provides. With very high or very long use the copper balance still deserves attention, one more reason for cycles instead of continuous use.
• Angiogenesis: TB-500 and BPC-157 promote new blood vessel formation in studies. From that a theoretical concern is derived that existing abnormal tissue could be supplied as well. There is no evidence for it, but it has not been specifically studied in humans either.
• Fatigue: brief fatigue after TB-500 doses is occasionally reported, usually mild.
• Evidence: systematic human safety data are missing for each of the four components, even more so for the combination with doubled peptide amounts.

If the solution turns gel-like or lumpy, do not use the vial. Slight cloudiness on its own is not a reason.

The unreconstituted powder is robust: normal room temperature (around 20 to 25 degrees) is fine, ideally dark and dry. For longer periods it can go in the fridge, but it does not have to.

Once reconstituted, the solution goes in the fridge (2 to 8 degrees) and keeps there for several months; the bacteriostatic water brings a preservative for that. At 2.2mg daily a vial is empty after around 7 weeks. The solution stays perfectly usable for that long. Do not freeze and do not leave it in the sun.

Swirling or shaking is both fine. The blue tint from the copper is part of it. Going through the same stopper repeatedly is normal, just wipe the cap each time first.